Fertility warning
This medicine may affect fertility.
Leaflet TRABECTEDINA STADA 1mg powder for concentrate for solution for infusion
- Product code:
- W70189001
- Quantity:
- 1
- Indicated for:
- cancer
- Route of administration:
- infusion
- Substance:
- trabectedin (antineoplastic agent)
- ATC
- L01CX01 — Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Other plant alkaloids and natural products
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Trabectedin is an antineoplastic agent used in the treatment of advanced soft tissue sarcomas and recurrent ovarian cancer. It is a compound derived from a natural product extracted from a marine organism, Ecteinascidia turbinata, and works by binding to DNA, inhibiting gene transcription, and inducing apoptosis in tumor cells.
Trabectedin is administered intravenously, usually in 3-week cycles, with the dose adjusted based on the patient's body weight and tolerability. It is often used in combination with pegylated liposomal doxorubicin for ovarian cancer treatment.
Common side effects include nausea, vomiting, fatigue, neutropenia, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as rhabdomyolysis, liver failure, or serious infections may occur. Careful monitoring of hematological and liver parameters is essential during treatment.
Trabectedin is a valuable therapeutic option for patients with sarcomas and ovarian cancer, contributing to prolonged survival and improved quality of life.
Trabectedin is administered intravenously, usually in 3-week cycles, with the dose adjusted based on the patient's body weight and tolerability. It is often used in combination with pegylated liposomal doxorubicin for ovarian cancer treatment.
Common side effects include nausea, vomiting, fatigue, neutropenia, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as rhabdomyolysis, liver failure, or serious infections may occur. Careful monitoring of hematological and liver parameters is essential during treatment.
Trabectedin is a valuable therapeutic option for patients with sarcomas and ovarian cancer, contributing to prolonged survival and improved quality of life.
General data about TRABECTEDINA STADA 1mg
- Substance:
- trabectedin
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W70189001
- Concentration:
- 1mg
- Pharmaceutical form:
- powder for concentrate for solution for infusion
- Quantity:
- 1
- Product type:
- Generic medicine
- Price:
- 4926.34 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for trabectedin
- 0.25mg
- 1mg